Lexicon Pharmaceuticals, Inc.

Equities

LXRX

US5288723027

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 20:38:07 14/01/2026 GMT			5-day change	1st Jan Change
1.245 ^USD	+3.75%		+6.41%	+8.26%

01-12	Lexicon Pharmaceuticals provides a business and pipeline update at the 44th annual J.P. Morgan healthcare conference	RE
12-18	Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) dropped from NASDAQ Biotechnology Index	CI

Lexicon Pharmaceuticals, Inc. Announces Clinical Data on Adipose Distribution in Non-Diabetic Patients to Be Presented At the 2025 Cardio Vascular Clinical Trialists Forum

Published on 12/05/2025 at 03:23 pm GMT

S&P Capital IQ

Lexicon Pharmaceuticals, Inc.

+3.75%

Lexicon Pharmaceuticals, Inc. announced clinical data on adipose tissue distribution in non-diabetic patients treated with sotagliflozin will be presented at the 22ndGlobal Cardio Vascular Clinical Trialists Forum (CVCT 2025). The conference is being held December 8-10, 2025, at the Mayflower Hotel in Washington, D.C. This data is from SOTA-P-CARDIA, a prospective, randomized, double-blind, placebo-controlled trial that exclusively enrolled patients with heart failure with preserved ejection fraction (HFpEF) and was conducted by Mount Sinai Medical Center in New York City.

Latest news about Lexicon Pharmaceuticals, Inc.

01-12	Lexicon Pharmaceuticals provides a business and pipeline update at the 44th annual J.P. Morgan healthcare conference	RE
12-18	Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) dropped from NASDAQ Biotechnology Index	CI
12-10	Lexicon Pharmaceuticals, Inc. Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Ayl-Coa Synthetase 5 Reinforcing the Scientific Rationale for Lx9851	CI
12-05	Lexicon Pharmaceuticals, Inc. Announces Clinical Data on Adipose Distribution in Non-Diabetic Patients to Be Presented At the 2025 Cardio Vascular Clinical Trialists Forum	CI
12-05	Clinical data on effect of sotagliflozin on adipose distribution in non-diabetic patients	RE
11-19	Lexicon Pharmaceuticals, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 05:00 PM
11-08	Lexicon Pharmaceuticals, Inc. Announces Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure Without Diabetes Presented At American Heart Association Annual Scientific Sessions 2025	CI
11-06	Lexicon Pharmaceuticals Inc files for offering of up to $75 million of common stock - SEC filing	RE
11-06	Relay Therapeutics, Inc. Appoint Board and Committee, Effective November 4, 2025	CI
11-06	Lexicon Pharmaceuticals, Inc., Q3 2025 Earnings Call, Nov 06, 2025
11-06	Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-06	Lexicon Pharma Q3 net loss narrows as R&D costs drops	RE
11-04	Lexicon Pharmaceuticals, Inc. Announces Data from Three Studies of Sotagliflozin to Be Presented At the Hypertrophic Cardiomyopathy Society and American Heart Association's Sessions 2025 in New Orleans	CI
14/10/25	Lexicon Pharmaceuticals, Inc. Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit	CI
22/09/25	Lexicon Pharmaceuticals Says FDA Delays Feedback on Zynquista Data	MT
22/09/25	Lexicon pharmaceuticals announces update on submission of additional data to U.S. FDA	RE
22/09/25	FDA Pushes Back Review of Lexicon Diabetes Drug Data	DJ
22/09/25	Lexicon expects delay in FDA feedback on additional data for its diabetes drug	RE
22/09/25	Lexicon expects delay in FDA feedback on additional data for its diabetes drug	RE
22/09/25	Lexicon Pharmaceuticals, Inc. Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista®? in Type 1 Diabetes	CI
17/09/25	Lexicon Pharmaceuticals, Inc. Announces the Presentation of Clinical Data from the Company's Phase 2B Progress Study for Its Investigational, AAK1-Inhibitor, Pilavapadin, for the Treatment of Diabetic Peripheral Neuropathic Pain	CI
08/09/25	Lexicon Pharmaceuticals Submits Additional Data to US FDA for Zynquista	MT
08/09/25	Lexicon submits new data to FDA supporting Zynquista's use in type 1 diabetes	RE
08/09/25	Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista®? in Type 1 Diabetes	CI
03/09/25	Lexicon Pharmaceuticals, Inc. Presents at Citi's Biopharma Back to School Conference, Sep-03-2025 01:45 PM

Chart Lexicon Pharmaceuticals, Inc.

Duration

Period

LXRX: Dynamic Chart

Company Profile

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.

Employees

103

Sector

Biotechnology & Medical Research

Calendar

01-15 - J.P. Morgan Healthcare Conference

More about the company